Academic Journal
Q1Clinical Pharmacokinetics
About Clinical Pharmacokinetics
About Clinical Pharmacokinetics
Clinical Pharmacokinetics is a peer-reviewed scholarly journal (Switzerland). It focuses on Q1. Publication coverage spans 1976-2026.
Key indicators: ISSN 1179-1926, 0312-5963; H-index 197; Impact Factor 4.0.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (197): Exceptionally high — 197 articles have each been cited at least 197 times. This indicates deep, sustained influence in the field.
- Impact Factor (4.0): Average citations per recent article. A solid figure indicating regular citation by the research community.
Publishing in Clinical Pharmacokinetics
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Clinical Pharmacokinetics?
1179-1926, 0312-5963.
What are Clinical Pharmacokinetics's metrics?
Impact Factor 4.0; H-index 197.
Is Clinical Pharmacokinetics peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Verified field sources
- Journal Impact Factor: 4.0 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2024 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Pharmacogenetics and Drug Metabolism; Antibiotics Pharmacokinetics and Efficacy; Pharmacological Effects and Toxicity Studies; Drug Transport and Resistance Mechanisms; Pharmaceutical studies and practices; Epilepsy research and treatment.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,990.00 USD; 3,890.00 EUR; 3,090.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Efsubaglutide Alfa: A Comprehensive Pharmacological Review
Haolin Zheng, Run Yan, Fan Jiang, Yi Li et al.
2026-10-13 · DOI: 10.1007/s40262-026-01713-6Physiologically Based Pharmacokinetic Modeling of Elexacaftor–Tezacaftor–Ivacaftor in Adults and Pediatric People with Cystic Fibrosis: Exploring Brain Exposure and Neuropsychiatric Adverse Events
Clotilde Vellat, Laurent Bourguignon, Sabine Cohen, Philippe Reix et al.
2026-10-09 · DOI: 10.1007/s40262-026-01712-7Application of Pharmacometric Modelling Towards Precise Dosing in Neonates, Infants and Toddlers: A Scoping Review
Ana S. Rodríguez-Báez, Nina Kreuzberger, Claire Iannizzi, Kamran Irfan et al.
2026-10-07 · DOI: 10.1007/s40262-026-01670-0Assessing the Influence of CYP3A4 Inhibitors on Voriconazole Exposure across CYP2C19 Genotypes: A Physiologically Based Pharmacokinetic Model Analysis
Sahithi Thotakura, Anil R. Maharaj
2026-10-07 · DOI: 10.1007/s40262-026-01703-8Pharmacokinetics of Efavirenz in Pregnancy and Postpartum with and Without First-line Tuberculosis Drugs: Results from IMPAACT P1026s
Marije Van Schalkwyk, Jiajia Wang, Adrie Bekker, Eric Decloedt et al.
2026-10-03 · DOI: 10.1007/s40262-026-01690-wStructured Evaluation of Model-Informed Precision Dosing of Mycophenolic Acid and Tacrolimus in Pediatric Patients with Kidney Disease
Astrid Heida, Elisabeth A. M. Cornelissen, Rob E. Aarnoutse, Brenda C. M. de Winter et al.
2026-09-30 · DOI: 10.1007/s40262-026-01708-3Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment
Anthéa Deschamps, Florence Gattacceca, Olivier Blin, Lionel Velly et al.
2026-09-30 · DOI: 10.1007/s40262-026-01701-wUnderstanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking
Jeffry Adiwidjaja, Alan V. Boddy, Andrew J. McLachlan
2026-09-30 · DOI: 10.1007/s40262-026-01698-2The Effect of Intrinsic Factors on the Pharmacokinetics of Once-Weekly Insulin Icodec in Type 1 and Type 2 Diabetes: A Population Pharmacokinetic Analysis of Phase II and Phase III trials
Niels R. Kristensen, Mundot P. Haridas, Athena Philis-Tsimikas, Rasmus Ribel-Madsen et al.
2026-09-30 · DOI: 10.1007/s40262-026-01710-9Metformin Pharmacogenetics in Heart Failure Patients with Reduced Ejection Fraction: Impact on Metformin and Growth Differentiation Factor-15 Plasma Levels
Anders Hostrup Larsen, Tore Bjerregaard Stage, Mette Marie Hougaard Christensen, Søren Feddersen et al.
2026-09-28 · DOI: 10.1007/s40262-026-01699-1Comparing the Predictive Performance of Machine Learning Models with a Newly Developed Population Pharmacokinetic Model for Busulfan in Paediatric Patients
Tianwu Yang, Maria Thastrup, Tania Nicole Masmas, Hilde Hylland Uhlving et al.
2026-09-22 · DOI: 10.1007/s40262-026-01702-9PBPK Modeling of Coproporphyrin I Reveals Frailty-Associated Changes in Hepatic OATP1B1 Function in Chinese Adults
Longjie Li, Mengfan Ye, Wenhang Xu, Xinyan Zhu et al.
2026-09-21 · DOI: 10.1007/s40262-026-01704-7Clinical Pharmacokinetics and Disposition of Imrecoxib
Shengnan Zhao, Charlie Li, Marlon C. Mallillin, Raimar Löbenberg et al.
2026-10 · DOI: 10.1007/s40262-026-01705-6Towards Model-Informed Precision Dosing of High-Dose Rifampicin: A Parsimonious Population Pharmacokinetic Model Capturing Saturation and Autoinduction in Tanzanian and South African Patients with Tuberculosis
Yuan J. Petermann, Bibie Said, Margaretha L. Sariko, Yann Thoma et al.
2026-09-15 · DOI: 10.1007/s40262-026-01674-wFrom Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib
Laura H. Bukkems, Benoit Blanchet, Jennifer Arrondeau, Marie Wislez et al.
2026-09-06 · DOI: 10.1007/s40262-026-01697-3Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors
Zaid N. Al Shirity, Paola Mian, Anouk Dontje, Anthonie J. van der Wekken et al.
2026-09-04 · DOI: 10.1007/s40262-026-01684-8Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with Hemophilia
Satyaprakash Nayak, Akiyuki Suzuki, Patanjali Ravva, Sangeeta Raje et al.
2026-10 · DOI: 10.1007/s40262-026-01695-5A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF
Justin D. Lutz, Neha Maharao, Tyrell Simkins, Kathleen Cheplo et al.
2026-10 · DOI: 10.1007/s40262-026-01694-6Effect of Rivoceranib 200 mg Once Daily on the Pharmacokinetics of a Cocktail Probe Substrate of Cytochrome P450 Enzymes: A Phase I Trial in Healthy Volunteers
David Nguyen, Xiaohui Tracey Wei, Xianzhang Meng, Laura Alexander et al.
2026-10 · DOI: 10.1007/s40262-026-01686-6Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters
Matthieu Gregoire, Steven C. Wallis, Paul G. Williams, Hayoung Won et al.
2026-10 · DOI: 10.1007/s40262-026-01659-9Reviews
Community Reviews
Version History
October 9, 2026 at 8:02 pm
September 25, 2026